Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesClinical efficacy and safety of zoledronic acid in prostate and breast cancer
Expert Review of Anticancer Therapy, 09/24/09
Doggrell SA – The anti–estrogen treatment for hormone–sensitive breast cancer and the androgen deprivation therapy for prostate cancer can lead to the development of osteoporosis and bone fractures. The efficacy and safety of zoledronic acid in osteoporosis secondary to hormone–sensitive cancers (prostate and breast), and in the bone metastases associated with these cancers are reviewed.
Related Articles
Is zoledronic acid an anticancer drug
Expert Opinion in Pharmacotherapy, 10/05/09
Relevance Score: 69%
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial
Obstetrics and Gynecology, 10/27/09
Relevance Score: 66%
Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy
The Journal of Urology, 10/16/09
Relevance Score: 66%
Combination of Two Medications Help Postmenopausal Women with Osteoporosis
MedLinePlus, 10/30/09
Relevance Score: 64%
Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis
Osteoporosis International, 10/30/09
Relevance Score: 64%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer
Cancer Science, 12/04/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Radical Prostatectomy for Prostate Cancer after Ileal Pouch-Anal Anastomosis Offers Oncologic Control and Sustains Quality of Life
Journal of the American College of Surgeons, 12/04/09
Article Search
Sponsor